Characterization of the anti-platelet actions of FK419, a novel non-peptide antagonist of platelet GPIIb/IIIa

Drug Development Research

Volumn 61, Issue 4, 2004, Pages 233-241

  Mihara, Kayoko ^a   Aoki, Toshiaki ^a   Moriguchi, Akira ^a   Yamamoto, Hiroko ^a   Maeda, Masashi ^a   Tojo, Nobuteru ^a   Yamanaka, Toshio ^a   Ohkubo, Mitsuru ^a   Matsuoka, Nobuya ^a   Seki, Jiro ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Bleeding; FK419; GPIIb IIIa antagonist; Platelet

Indexed keywords

2 ACETYLAMINO 3 [[1 [3 (PIPERIDIN 4 YL)PROPIONYL]PIPERIDIN 3 YLCARBONYL]AMINO]PROPIONIC ACID; 4 (4 AMIDINOPHENOXY)BUTYRYLASPARTYLVALINE; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; FK 419; LAMIFIBAN; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

EID: 4944241817     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10382     Document Type: Article

References (26)

1. Albelda SM, Daise M, Levine EM, Buck CA. 1989. Identification and characterization of cell-substratum adhesion receptors on cultured human endothelial cells. J Clin Invest 83:1992-2002.
2. Anders R, Kleiman J, Nicholson N, Wazowicz B, Burns D. 2001. Xemilofiban/orbofiban: insight into drug development. Cardiovasc Drug Rev 19:116-132.
3. Aoki T, Cox D, Senzaki K, Seki J, Tanaka A, Takasugi H, Motoyama Y. 1996. The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic GPIIB/IIIA antagonist. Thromb Res 81:439-450.
4. Aoki T, Harada K, Seki J, Tanaka A, Takasugi H, Motoyama Y. 1999. FK633: a potent and selective platelet GPIIb/IIIa antagonist. Cardiovasc Drug Rev 17:147-159.
5. Bednar MM, Gross CE. 1999. Aspirin reduces experimental cerebral blood flow in vivo. Neurol Res 21:488-490.
6. CAPTURE Investigators. 1997. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 349:1429-1435.
7. Cieutat AM, Rosa JP, Letourneur F, Poncz M, Rifat S. 1993. A comparative analysis of cDNA-derived sequences for rat and mouse beta 3 integrins (GPIIIA) with their human counterpart. Biochem Biophys Res Commun 193:771-778.
8. Coller BS, Anderson K, Weisman HF. 1995. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 74:302-308.
9. Cook N, Kottirsch G, Zerwes H-G. 1994. Platelet glycoprotein IIb/ IIIa antagonists. Drugs Fut 19:135-159.
10. Doggrell SA. 2001. Clinical trials with glycoprotein IIb/IIIa antagonists: no benefit without bleeding? Drugs Today (Barc) 37:509-531.
11. Dooley M, Goa KL. 1999. Lamifiban. Drugs 57:215-221; discussion 222-223.
12. EPIC Investigators. 1994. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961.
13. Fisher M, Levine PH, Fullerton AL, Forsberg A, Duffy CP, Hoogasian JJ, Drachman DA. 1982. Marker proteins of platelet activation in patients with cerebrovascular disease. Arch Neurol 39:692-695.
14. Fitzgerald DJ, Roy, L, Catella F, FitzGerald GA. 1986. Platelet activation in unstable coronary disease. N Engl J Med 315:983-989.
15. Gimple LW, Gold HK, Leinbach RC, Coller BS, Werner W, Yasuda T, Johns JA, Ziskind AA, Finkelstein D, Collen D. 1989. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 80:581-588.
16. Horwitz PA, Berlin JA, Sauer WH, Laskey WK, Krone RJ, Kimmel SE. 2003. Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry). Am J Cardiol 91:803-806.
17. Lind SE. 1991. The bleeding time does not predict surgical bleeding. Blood 77:2547-2552.
18. McClellan KJ, Goa KL. 1998. Tirofiban. A review of its use in acute coronary syndromes. Drugs 56:1067-1080.
19. Ohkubo M, Takahashi F, Yamanaka T, Kato M. 1997. N-[(R)-1-{3-(4- piperidyl) propionyl-3-piperidylcarbonylL]-2(S)-acetylamino-beta-alanine as fibrinogen receptor antagonist. Osaka, Japan: Fuijiswa Pharmaceutical Co., Ltd. WO9733869.
20. Phillips DR, Charo IF, Scarborough RM. 1991. GPIIb-IIIa: the responsive integrin. Cell 65:359-362.
21. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. 1986. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp: specific adhesion receptors. Science 231:1559-1562.
22. Ruggeri ZM, Dent JA, Saldivar E. 1999. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 94:172-178.
23. Savage B, Almus-Jacobs F, Ruggeri ZM. 1998. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 94:657-666.
24. Schror K. 1995. Antiplatelet drugs. A comparative review. Drugs 50:7-28.
25. Topol EJ, Byzova TV, Plow EF. 1999. Platelet GPIIb-IIIa blockers. Lancet 353:227-231.
26. Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffmann T. 1989. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 83:288-297.